

SPARC/Sec/SE/2023-24/050

September 26, 2023

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Symbol: SPARC

Scrip Code: 532872

Dear Sir/ Madam,

Sub: Intimation of incorporation of a Wholly Owned Subsidiary Company (WOS)

Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


With reference to above mentioned subject matter and pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015 (LODR), we hereby inform that the Company has incorporated a WOS namely "SPARCLIFE Inc." in Delaware, US.

The details/disclosures in respect of the said WOS, as required under Regulation 30 of the SEBI (LODR), Regulations, 2015, read with Schedule III thereto and the SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated 11th July,2023, are enclosed as Annexure A.

You are requested to take the above information on record.

Yours faithfully,

For Sun Pharma Advanced Research Company Limited



Kajal Damania

Company Secretary and Compliance Officer

Encl: As above

Annexure A

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover, etc	<p>SPARCLIFE, Inc., a WOS, has been incorporated in US with effect from September 25, 2023.</p> <p>The total number of shares of stock which the corporation shall have authority to issue is 5,000 shares of Common Stock, par value USD 0.001.</p> <p>Paid up Share Capital: 50 Shares of Common Stock of value USD 0.001 each at the consideration of USD 50,000</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	No
3	Industry to which the entity being acquired belongs.	Bio-pharmaceutical company
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	The main object of the Company is to obtain the services of the WOS which would engage a team of seasoned professionals based in US who coordinates, reviews and monitors the global clinical trials being conducted through various CROs in US by the Company.



5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition.	Not Applicable
7	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash Consideration
8	Cost of acquisition or the price at which the shares are acquired.	50 shares of common stock at par value USD 0.001 per share for USD 50,000 in cash.
9	Percentage of shareholding /control acquired and/ or number of shares acquired.	Entire Subscription
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	SPARCLIFE, Inc is incorporated as a WOS in Delaware, US. The WOS is yet to commence its operations.

